Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017505 | 0.88 | ADORA3 (0.50) | FEN1PARP1DAOADORA3ADORA2A | |
| SCHEMBL27438347 | 0.82 | DAO (0.60) | FEN1PARP1DAOACHEADORA3 | |
| SCHEMBL16657358 | 0.79 | DAO (0.47) | FEN1PARP1DAOADORA3ADORA2A | |
| SCHEMBL12506543 | 0.79 | FEN1 (0.66) | FEN1PARP1DAOACHEADORA3 | |
| SCHEMBL7650487 | 0.77 | ADORA3 (0.61) | FEN1ADORA3ADORA2AADORA1LMNA | |
| SCHEMBL29407350 | 0.77 | ADORA3 (0.61) | FEN1ADORA3ADORA2AADORA1LMNA | |
| SCHEMBL18687482 | 0.76 | FEN1 (1.00) | FEN1PARP1DAOACHE | |
| SCHEMBL15624105 | 0.75 | CYP1A2 (0.62) | FEN1PARP1DAOACHEADORA3 | |
| SCHEMBL11870266 | 0.75 | FEN1 (0.60) | FEN1PARP1DAOACHEADORA3 | |
| SCHEMBL22016540 | 0.74 | ADORA3 (0.50) | FEN1PARP1DAOADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | FEN1 4719/4885PARP1 1100/4885DAO 4307/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | FEN1 4719/4885PARP1 1100/4885DAO 4307/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | FEN1 4828/4885PARP1 1472/4885DAO 4523/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | FEN1 4719/4885PARP1 1100/4885DAO 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.